Subject name, address	Effective date
CHICAGO, IL	
PISANO, SALLIE LACEY, WA	3/20/2005
POOLE, WILLIAM EAGLESVILLE, TN	3/20/2005
POULSEN, JERRY W VALLEY CITY, UT	3/20/2005
POYATOS, DANILO VICTORVILLE, CA	3/20/2005
PRONTO, DAVID HUDSON FALLS, NY	3/20/2005
PRUGH, JAMES SCOTTSDALE, AZ	3/20/2005
RAIMAN, GARII CONCORD, CA	3/20/2005
ROSS, LINDA EL DORADO, KS	3/20/2005
SABATINO, DAVID ELIZABETHTON, TN	3/20/2005
SARVIS, AMANDA FREMONT, NC	3/20/2005
SAVAGE, SANDRA S BOSTON, MA	3/20/2005
SAYED, SAQUIB CRANFORD, NJ	3/20/2005
SCHAEFFER, BRANDON CHICAGO, IL	3/20/2005
SCHWARZ, ANN RANDOLPH, MA	3/20/2005
SCOTT, OTIS ABINGTON, PA	3/20/2005
SEJALBO, MARYANN HAYWARD, CA	3/20/2005
SHELL, JOAN-MARIE PORT HADLOCK, WA	3/20/2005
SHERMAN, AHRON EUREKA, CA	3/20/2005
SHINDORE, SHREELAL NAPLES, FL	3/20/2005
SHORT, LEA ANN NEW ALBANY, IN	3/20/2005
SILVA, LINDA IONE, CA	3/20/2005
SIMPSON, LISA LOUISVILLE, KY	3/20/2005
SMITH, LESLIE TEMPE, AZ	3/20/2005
SMITH, SUSAN ROCKFORD, IL	3/20/2005
SMITH, TRICIA OSSIPEE, NH	3/20/2005
SOUSA, BONNIE STOCKTON, CA	3/20/2005
STAPLETON, KELLY CRESTWOOD, IL	3/20/2005
STELLHORN, JEANNE CAHOKIA, IL	3/20/2005
STEVENS, ANNA ROOSEVELT, UT	3/20/2005
STOLLOF, KELLY INDIO, CA	3/20/2005
STROMBERG, WILLIAM DE SOTO, IL	3/20/2005
SUPPLEE, PENNY WEST CHESTER, PA	3/20/2005
SUSS, BEVERLY GRAFTON, MA	3/20/2005
SUTTON, CURTIS LAYTON, UT	3/20/2005
TAYLOR, REGINA CHICAGO, IL	3/20/2005
TEE, MIKE AURORA, CO	3/20/2005
VAHLE, TREVOR FRUITA, CO	3/20/2005
VALENCIA, MARIA DENVER, CO	3/20/2005
VALENTINE, CHRISTINE RICHMOND, VA	3/20/2005
VANDENBOS, GREGORY RENO, NV	3/20/2005
VAWTER, KAREN COEUR D'ALENE, ID	3/20/2005
WALLACE, PATRICK ABINGDON, VA	3/20/2005
WIJNHAMER, JAN BELLINGHAM, WA	3/20/2005
WILLIAMS, MICHELLE PAINTSVILLE, KY	3/20/2005
WILSON, DONNA JASPER, TX	3/20/2005
WRIGHT, STEVIE SEYMOUR, TN	3/20/2005
YOUNG, SANDRA CARTERVILLE, IL	3/20/2005
ZEGARRA, GLORIA GLENDALE, CA	3/20/2005
FRAUD/KICKBACKS/PROHIBITED ACTS/ SETTLEMENT AGREEMENTS	
MED-CON, INC PAINTSVILLE, KY	12/29/2004
PRICE, HARRY MARTINSBURG, VA	9/20/2004
SHAW, JOHN PAINTSVILLE, KY	12/29/2004
OWNED/CONTROLLED BY CONVICTED ENTITIES	
AMERICAN FAMILY PHARMACEUTICALS, INC NAPLES, FL	3/20/2005
CONVENIENT MEDICAL SERVICES, INC NAPLES, FL	3/20/2005
LADD MANAGEMENT CORPORATION LEAWOOD, KS	3/20/2005
MARIN CHIROPRACTIC, INC VAN NUYS, CA	3/20/2005
MICHAEL E SMITH, D P M, P A ORLANDO, FL	3/20/2005
MOBILE DENTISTRY, LLC NEW CASTLE, PA	3/20/2005
PAIN RELIEF MEDICAL CENTER VAN NUYS, CA	3/20/2005
S FT MYERS MEDICAL CENTER, INC FT MYERS, FL	3/20/2005
SHREELAL M SHINDORE, MD, PA NAPLES, FL	3/20/2005
SYNERGISTICS MEDICAL CARE PA LEAWOOD, KS	3/20/2005
DEFAULT ON HEAL LOAN	
BAKER, WALTER VALLEJO, CA	3/20/2005
BARNETT, RUTH DETROIT, MI	2/1/2005
BELL, HERMAN LOS ANGELES, CA	3/20/2005
CHIANG, PHILIP MOUNTAIN VIEW, CA	3/20/2005
FERNANDO, ANTONIO PHILADELPHIA, PA	3/20/2005
LINDLY, MAURICE SALINAS, CA	3/20/2005
MULLINAX, JEFFREY WINDSOR, CA	3/20/2005
NEWBY, EDGAR LAWTON, OK	3/20/2005
PASCALE, MICHELE AUGUSTA, GA	3/20/2005
RAPPA, RICHARD N HAVEN, CT	3/20/2005
CMP	
O'CONNOR, THOMAS MILWAUKEE, WI	2/28/2005

Dated: March 2, 2005.

Katherine B. Petrowski,

Director, Exclusions Staff, Office of Inspector General.

[FR Doc. 05–4680 Filed 3–9–05; 8:45 am]

BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Assessment of the Use of Special Funding on Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes

SUMMARY: In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: *Title:* Assessment of the Use of Special Funding for Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997 (Pub. L. 105–33), the FY 2001 Consolidated Appropriations Act (Pub. L. 106–554), and the Public Health Service Act Amendment for Diabetes (Pub. L. 107–360). *Type of Information Collection Request:* Revision, OMB control number 0925–0503; expiration date: 06/30/2005. *Need and Use of Information Collection:* This

survey will be one source of input into a statutorily mandated assessment and report to the Congress on special funding for research on type 1 diabetes provided by the Balanced Budget Act of 1997, (Pub. L. 105–33), the FY 2001 Consolidated Appropriations Act, (Pub. L. 106–554), and the Public Health Service Act Amendment for Diabetes, (Pub. L. 107–360). Collectively, these Acts provided $1.14 billion in special funds to the Department of Health and Human Services (HHS) for research aimed at understanding, treating and preventing type 1 diabetes and its complications. The Secretary of HHS subsequently designated to NIDDK the lead responsibility in the Department for developing a process for allocation of these funds. The primary objective of the survey is to gain information, via a brief questionnaire, from NIH research grantees, who were the primary recipients of these special funds, concerning their views on the impact of the type 1 diabetes research funding with respect to: (1) Advancing scientific accomplishments involving innovative, clinically relevant, and multidisciplinary research on type 1 diabetes; (2) developing resources or reagents useful for type 1 diabetes research; and (3) increasing the number and quality of type 1 diabetes investigators. The responses will provide valuable information concerning how the funds have facilitated research as intended by these Acts of Congress. The results will also help determine how research progress from these special congressional initiatives fits within the continuum of diabetes research, and how these funds have contributed to the field of type 1 diabetes research and NIH efforts to combat this challenging health problem. Information from this study will aid in evaluation of the process by which the research goals for use of the special type 1 diabetes funds have been developed and are being pursued. Responses already collected from this survey were analyzed as part of an interim program assessment that was published by the NIDDK in April, 2003 *http://www.niddk.nih.gov/federal/planning/type 1_specialfund/.* This revised survey will contribute to a statutorily mandated report, due to Congress on January 1, 2007, evaluating the process and efforts under this program and assessing research initiatives funded by these Acts of Congress.

Frequency of Response: The initial survey will require a one time response; though, respondents may be contacted again in the event of future congressionally mandated reports on the use of the special type 1 diabetes research funds.

Affected Public: Research scientists who received the special funds about which Congress has mandated in law the requirements for an evaluation report. *Type of Respondents:* Laboratory and clinical investigators who have received support from the special type 1 diabetes funds provided under the laws previously cited. The annual reporting burden is as follows: *Estimated Number of Respondents:* 500; *Estimated Number of Responses per Respondent:* 1 (Respondents will be given one questionnaire containing an estimated fifteen questions.); *Average Burden Hours Per Response:* 1; and *Estimated Total Annual Burden Hours Requested:* 500. The annualized total cost to respondents is estimated at: $25,000. It is expected that the respondents will be contacted vie e-mail and that their responses will be collected through an Internet-accessible questionnaire. These measures will reduce the burden on the respondents and the overall costs of administering the study. Because different types of awards have been made with the special type 1 diabetes funds, the questionnaire may be tailored such that respondents will only be asked to answer a subset of questions that pertain to their particular type of award(s). No respondent will be asked to answer more than a total of fifteen questions, at least one-third of which will be answered with a ''yes'' or ''no'' or a one-word response. There are no Capital Costs, Operating or Maintenance Costs to report.

Request For Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Shefa Gordon, Office of Scientific Program and Policy Analysis, NIDDK, NIH, Building 31, Room 9A31, 9000 Rockville Pike, Bethesda, MD 20892, or call non-toll-free number 301–496–6623 or e-mail your request, including your address to: *gordonshefa@mail.nih.gov.*

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: March 2, 2005.

Lynell Nelson,

Project Clearance Liaison, NIDDK, National Institutes of Health.

[FR Doc. 05–4674 Filed 3–9–05; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: (301) 496–7057; fax: (301) 402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Dimer Inhibitory Peptides of CXCR4 as a Possible Novel Therapy for Cancer

Jinhai Wang and Michael Norcross (FDA),
DHHS Reference No. E–037–2005/0—Research Tool,
Licensing Contact: John Stansberry; (301) 435–5236; *stansbej@mail.nih.gov.*

This invention may control or inhibit cancer metastases by targeting